Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 26;29(2):510-515.
doi: 10.3390/curroncol29020046.

Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors

Taymeyah Al-Toubah  1 , Brian Morse  2 , Jonathan Strosberg  1
Affiliations

Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors

Taymeyah Al-Toubah et al. Curr Oncol. .

Abstract

The capecitabine/temozolomide regimen has significant activity in pancreatic NETs; however, data are limited in NETs of the small bowel (midgut). A retrospective study of all patients with metastatic midgut NETs seen at Moffitt Cancer Center between January 2008 and June 2019 treated with CAPTEM was conducted. 32 patients with proven or suspected well-differentiated primary small bowel NETs (excluding duodenum) were identified. 6 patients were found to have a radiographic response (19%), 5 of whom had high-grade disease. Only one patient among 23 with low/intermediate-grade disease responded (4%), whereas the response rate for patients with high-grade disease was 56%. Among patients with low/intermediate-grade disease, 44% discontinued due to poor tolerability. The CAPTEM regimen appears to have an activity in patients with high-grade small bowel NETs and is largely inactive in patients with low/intermediate-grade tumors.

Keywords: capecitabine; captem; carcinoid; midgut; neuroendocrine tumors; small bowel; temozolomide.

PubMed Disclaimer

Conflict of interest statement

J. Strosberg–Ipsen (Speaker bureau) and Novartis (Consultant); B. Morse and T. Al–Toubah declare no conflict of interest.

Figures

Figure 1
Figure 1
Progression-free survival, stratified by tumor grade.
Figure 2
Figure 2
Overall survival, stratified by tumor grade.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Dasari A., Shen C., Halperin D., Zhao B., Zhou S., Xu Y., Shih T., Yao J.C. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients with Neuroendocrine Tumors in the United States. JAMA Oncol. 2017;3:1335–1342. doi: 10.1001/jamaoncol.2017.0589. - DOI - PMC - PubMed
    1. Das S., Dasari A. Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors. Ther. Adv. Med. Oncol. 2021;13:17588359211018047. doi: 10.1177/17588359211018047. - DOI - PMC - PubMed
    1. Das S., Dasari A. Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences? Curr. Oncol. Rep. 2021;23:43. doi: 10.1007/s11912-021-01029-7. - DOI - PMC - PubMed
    1. Raymond E., Dahan L., Raoul J.L., Bang Y.J., Borbath I., Lombard-Bohas C., Valle J., Metrakos P., Smith D., Vinik A., et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 2011;364:501–513. doi: 10.1056/NEJMoa1003825. - DOI - PubMed
    1. Yao J.C., Pavel M., Lombard-Bohas C., Van Cutsem E., Voi M., Brandt U., He W., Chen D., Capdevila J., de Vries E.G.E., et al. Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers from the Randomized, Phase III RADIANT-3 Study. J. Clin. Oncol. 2016;34:3906–3913. doi: 10.1200/JCO.2016.68.0702. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources